TORONTO – PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) (TSXV: PSYB) announced that the company’s subordinate voting shares will commence trading on the TSX Venture Exchange under the ticker symbol “PSYB”.
On February 19, 2021, the company announced the closing of its qualifying transaction with PsyBio Therapeutics, Inc., a US-based biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The transaction has now received all final approvals, including that of the TSXV.
“Listing on the TSXV is an important milestone for PsyBio as we enter the public market with the goal of enhancing our visibility within the investment community and broadening our investor base to build long-term shareholder value. Given our platform’s ability to efficiently develop next-generation psychoactive compounds, we envision building a company with the potential to help transform the treatment of mental health challenges and other disorders,” commented Evan Levine, PsyBio’s CEO.
PsyBio is a US-based biotechnology company developing a new class of drugs intended for the potential treatment of mental health challenges and other disorders. In collaboration with Miami University based in Oxford, Ohio, PsyBio has retained the global exclusive rights to a proprietary platform technology that biologically synthesizes psilocybin and other targeted next-generation psychoactive compounds that are produced naturally in fungi and plants. Management of PsyBio expects that the technology will enable the rapid generation of these highly stable psychoactive compounds cheaper, faster and greener than other published methods.
We seek Safe Harbor.